Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VTV THERAPEUTICS INC.

(VTVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.

Number of employees : 25 people.
Sales per Business
20192020Delta
Orally Administered Small Molecule Drug2.76100%6.41100% +132.05%
USD in Million
Sales per region
20192020Delta
United States2.76100%6.41100% +132.05%
USD in Million
Managers
Name Title Age Since
Deepa Prasad President, Chief Executive Officer & Director 40 -
Rudy C. Howard EVP, Chief Financial & Accounting Officer 61 2015
Aaron H. Burstein, Dr. Senior Vice President-Clinical Development - -
Carmen Valcarce, Dr. Chief Scientific Officer & Executive VP - -
Noel Joseph Spiegel Independent Director 72 2015
John A. Fry Independent Director 61 2016
Howard L. Weiner, Dr. Independent Director 74 2017
Robert C. Andrews, Dr. SVP-Chemistry &1 Pharmaceutical Development - -
Samuel B. Rollins, Dr. Vice President-Intellectual Property - 2004
Trey M. Lambert Senior Vice President & General Counsel - 2020
Members of the board
Name Title Age Since
Robin E. Abrams Executive Chairman 56 2020
Noel Joseph Spiegel Independent Director 72 2015
John A. Fry Independent Director 61 2016
Howard L. Weiner, Dr. Independent Director 74 2017
Hersh Kozlov Director 71 -
Richard S. Nelson Director 48 2020
Deepa Prasad President, Chief Executive Officer & Director 40 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,942,777 30,244,233 45.2% 0 0.0% 33.6%
Stock B 1 23,093,860 0 0.0% 0 0.0%
Shareholders
NameEquities%
Ronald Owen Perelman 36,606,212 60.8%
The Vanguard Group, Inc. 1,751,434 2.91%
Heights Capital Management, Inc. 1,229,153 2.04%
Frazier Management LLC 1,062,000 1.76%
GMT Capital Corp. 939,100 1.56%
Franklin Advisers, Inc. 835,323 1.39%
Wellington Management Co. LLP 820,390 1.36%
TIAA-CREF Investment Management LLC 630,227 1.05%
Massachusetts Financial Services Co. 455,553 0.76%
Royce & Associates LP 363,000 0.60%
Brand Portfolio
In partnership withAllbrands.markets
More brands of vTv Therapeutics Inc.